FDA Denies Vanda’s Jet Lag sNDA, Citing Inadequate 5- and 8-Hour Phase Advance Trials
On January 8 2026, FDA’s CDER rejected Vanda Pharmaceuticals’ NDA supplement for HETLIOZ® (tasimelteon) for jet lag, deeming its 5- and 8-hour phase advance trials insufficient analogs to real-world travel. Vanda plans to contest the ruling by highlighting positive trial efficacy and a favorable D.C. Circuit decision.
1. FDA Issues Non-Approval Letter for HETLIOZ® sNDA
On January 8, 2026, Vanda Pharmaceuticals received a decision letter from the FDA’s Center for Drug Evaluation and Research stating that the supplemental New Drug Application for HETLIOZ® (tasimelteon) in jet lag disorder cannot be approved in its current form. Although the FDA acknowledged positive efficacy signals from controlled clinical trials, it concluded that phase advance protocols (5-hour and 8-hour bedtime shifts) do not sufficiently mirror real-world jet travel conditions, which include variables such as reduced oxygen pressure, confined quarters, noise and lighting changes.
2. Vanda Disputes FDA’s Interpretation of Clinical Models
Vanda Pharmaceuticals publicly disagrees with the FDA’s assessment, arguing that phase advance models are widely accepted in circadian rhythm research and reliably reproduce the core misalignment underlying eastward jet lag. The company cites convergent evidence from both simulated and actual transatlantic travel studies demonstrating statistically significant improvements in sleep duration, latency to persistent sleep and next-day alertness. Vanda also highlights a decade-long safety record for tasimelteon, noting predominantly mild adverse events in approved indications.
3. Judicial and Collaborative Framework Context
This regulatory setback follows a U.S. Court of Appeals decision in August 2025 that vacated a prior FDA refusal, describing Vanda’s evidence as “specific, reasoned, and rooted in evidence” and criticizing the FDA’s initial review as cursory. Under a collaborative framework agreement reached in October 2025, the FDA committed to an expedited re-review of the jet lag application by January 7, 2026. Vanda contends that the latest decision does not fully reflect the court’s mandate for meaningful engagement with the submitted data.
4. Company Response and Forward Plan
Vanda remains committed to advancing its jet lag application and intends to work constructively with the FDA to address outstanding concerns. The company is evaluating all appropriate avenues, including additional analyses or trial data, to secure approval. Management emphasizes that approval would unlock a significant new indication for HETLIOZ®, which already serves patients with Non-24-Hour Sleep-Wake Disorder and sleep disturbances in Smith-Magenis Syndrome, potentially expanding its addressable market among global travelers.